FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - GSK (NYSE:GSK)

FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - GSK (NYSE:GSK)

On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. The Blenrep approval is supported by data from the pivotal DREAMM-7 phase 3 trial. Multiple myeloma is the third most common blood cancer globally and is …

Blenrep Returns: ADC Combo Approved for R/R MM

Belantamab mafodotin remains in development, with its maker, GlaxoSmithKline, aiming for an upfront MM indication. Medscape Medical News Source link : https://www.medscape.com/viewarticle/blenrep-returns-adc-combo-approved-r-r-mm-2025a1000t27?src=rss Author : Publish date : 2025-10-24 16:01:00 Copyright for syndicated content belongs to the linked Source. The post Blenrep Returns: ADC Combo Approved for R/R MM first appeared on News Health.

FDA approves Blenrep for relapsed or refractory multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved GSK‘s Blenrep (belantamab mafodotin) for adults with relapsed or refractory multiple myeloma. The approval covers the use of Blenrep in combination with dexamethasone and Velcade (bortezomib) in myeloma patients who have received at least two prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent. “Today’s FDA approval of Blenrep is another significant mil…

GSK’s Blenrep gains FDA approval for myeloma treatment

GSK has received US Food and Drug Administration (FDA) approval for Blenrep to be used along with BVd for multiple myeloma.

GSK Plc Gains FDA Approval For Blenrep Combination In Multiple Myeloma

GSK plc (LON:GSK/NYSE: GSK) has announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory (IMID) agent. The Blenrep approval is supported by data from th…

FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.